Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 1;9(1):62-69.
doi: 10.1001/jamaoncol.2022.5843.

Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial

Anthony E Mascia  1   2 , Emily C Daugherty  1   2 , Yongbin Zhang  1   2 , Eunsin Lee  1   2 , Zhiyan Xiao  1   2 , Mathieu Sertorio  2 , Jennifer Woo  3 , Lori R Backus  1 , Julie M McDonald  1 , Claire McCann  3 , Kenneth Russell  3 , Lisa Levine  3 , Ricky A Sharma  3 , Dee Khuntia  3 , Jeffrey D Bradley  4 , Charles B Simone 2nd  5 , John P Perentesis  1 , John C Breneman  1   2
Affiliations

Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial

Anthony E Mascia et al. JAMA Oncol. .

Erratum in

  • Change of Article Status to Open Access.
    [No authors listed] [No authors listed] JAMA Oncol. 2023 May 1;9(5):728. doi: 10.1001/jamaoncol.2023.0218. JAMA Oncol. 2023. PMID: 36862393 Free PMC article. No abstract available.

Abstract

Importance: To our knowledge, there have been no clinical trials of ultra-high-dose-rate radiotherapy delivered at more than 40 Gy/sec, known as FLASH therapy, nor first-in-human use of proton FLASH.

Objectives: To assess the clinical workflow feasibility and treatment-related toxic effects of FLASH and pain relief at the treatment sites.

Design, setting, and participants: In the FAST-01 nonrandomized trial, participants treated at Cincinnati Children's/UC Health Proton Therapy Center underwent palliative FLASH radiotherapy to extremity bone metastases. Patients 18 years and older with 1 to 3 painful extremity bone metastases and life expectancies of 2 months or more were eligible. Patients were excluded if they had foot, hand, and wrist metastases; metastases locally treated in the 2 weeks prior; metal implants in the treatment field; known enhanced tissue radiosensitivity; and implanted devices at risk of malfunction with radiotherapy. One of 11 patients who consented was excluded based on eligibility. The end points were evaluated at 3 months posttreatment, and patients were followed up through death or loss to follow-up for toxic effects and pain assessments. Of the 10 included patients, 2 died after the 2-month follow-up but before the 3-month follow-up; 8 participants completed the 3-month evaluation. Data were collected from November 3, 2020, to January 28, 2022, and analyzed from January 28, 2022, to September 1, 2022.

Interventions: Bone metastases were treated on a FLASH-enabled (≥40 Gy/sec) proton radiotherapy system using a single-transmission proton beam. This is consistent with standard of care using the same prescription (8 Gy in a single fraction) but on a conventional-dose-rate (approximately 0.03 Gy/sec) photon radiotherapy system.

Main outcome and measures: Main outcomes included patient time on the treatment couch, device-related treatment delays, adverse events related to FLASH, patient-reported pain scores, and analgesic use.

Results: A total of 10 patients (age range, 27-81 years [median age, 63 years]; 5 [50%] male) underwent FLASH radiotherapy at 12 metastatic sites. There were no FLASH-related technical issues or delays. The average (range) time on the treatment couch was 18.9 (11-33) minutes per patient and 15.8 (11-22) minutes per treatment site. Median (range) follow-up was 4.8 (2.3-13.0) months. Adverse events were mild and consistent with conventional radiotherapy. Transient pain flares occurred in 4 of the 12 treated sites (33%). In 8 of the 12 sites (67%) patients reported pain relief, and in 6 of the 12 sites (50%) patients reported a complete response (no pain).

Conclusions and relevance: In this nonrandomized trial, clinical workflow metrics, treatment efficacy, and safety data demonstrated that ultra-high-dose-rate proton FLASH radiotherapy was clinically feasible. The treatment efficacy and the profile of adverse events were comparable with those of standard-of-care radiotherapy. These findings support the further exploration of FLASH radiotherapy in patients with cancer.

Trial registration: ClinicalTrials.gov Identifier: NCT04592887.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Mascia reported grants and personal fees from Varian Medical Systems during the conduct of the study. Dr Daugherty reported personal fees from Varian Medical Systems during the conduct of the study. Dr Sertorio reported grants from Varian Medical Systems during the conduct of the study. Ms Woo reported employment at Varian Medical Systems, the commercial sponsor of the study. Dr McCann reported employment at Varian Medical Systems, the commercial sponsor of the study. Dr Russell reported employment at Varian Medical Systems, the commercial sponsor of the study. Dr Levine reported employment at Varian Medical Systems, the commercial sponsor of the study. Dr Sharma reported employment at Varian Medical Systems, the commercial sponsor of the study. Dr Khuntia reported employment at Varian Medical Systems, the commercial sponsor of the study, as well as multiple FLASH patents issued. Dr Bradley reported grants and personal fees from Varian Medical Systems outside the submitted work. Dr Simone reported personal fees from Varian Medical Systems during the conduct of the study. Dr Perentesis reported grants from Varian Medical Systems, Bristol Myers Squibb, Jazz Pharmaceuticals, and Incyte outside the submitted work. Dr Breneman reported funds from Varian Medical Systems to institute during the conduct of the study and personal fees from Varian Medical Systems. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Sample FLASH Treatment Plan and Bragg Curve Showing Radiation Dose in Color Wash
A, Axial computed tomography (CT) through a lesion treated in the right distal femur. B, Coronal CT through the same lesion. C, The radiation dose, drawn as a blue line, as a function of depth of penetration into the body for FLASH delivery with a 250-MeV transmission beam. The radiation dose is represented on the vertical axis, with depth of penetration into the body on the horizontal axis. The yellow box on the aqua-colored bar represents the position of the tumor in the radiation field, and the brighter red spot is the location of the increased dose at the Bragg peak, occurring outside of the patient’s body. In all panels, darker red color indicates higher dose.
Figure 2.
Figure 2.. CONSORT Participant Flow Diagram
Figure 3.
Figure 3.. Posttreatment Hyperpigmentation
Photographs of a transient, mild hyperpigmentation adverse event in the area of FLASH treatment in a single patient. The photographs may have been taken under different lighting conditions and/or with different cameras. To facilitate comparison across images, the brightness was uniformly decreased and the warmth uniformly increased in panel C, and the brightness was uniformly increased in panel D.
See this image and copyright information in PMC

Comment in

References

    1. Prempree T, Michelsen A, Merz T. The repair time of chromosome breaks induced by pulsed x-rays on ultra-high dose-rate. Int J Radiat Biol Relat Stud Phys Chem Med. 1969;15(6):571-574. doi:10.1080/09553006914550871 - DOI - PubMed
    1. Favaudon V, Caplier L, Monceau V, et al. . Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice. Sci Transl Med. 2014;6(245):245ra93. doi:10.1126/scitranslmed.3008973 - DOI - PubMed
    1. Montay-Gruel P, Petersson K, Jaccard M, et al. . Irradiation in a flash: unique sparing of memory in mice after whole brain irradiation with dose rates above 100Gy/s. Radiother Oncol. 2017;124(3):365-369. doi:10.1016/j.radonc.2017.05.003 - DOI - PubMed
    1. Loo JB, Schuler E, Lartey F, et al. . Delivery of ultra-rapid flash radiation therapy and demonstartion of normal tissue sparing after abdominal irradiation of mice. Int J Radiat Oncol Biol Phys. 2017;98(2)(suppl):E16. doi:10.1016/j.ijrobp.2017.02.101 - DOI
    1. Field SB, Bewley DK. Effects of dose-rate on the radiation response of rat skin. Int J Radiat Biol Relat Stud Phys Chem Med. 1974;26(3):259-267. doi:10.1080/09553007414551221 - DOI - PubMed

Publication types

Associated data